Literature DB >> 10938049

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

A I Adler1, I M Stratton, H A Neil, J S Yudkin, D R Matthews, C A Cull, A D Wright, R C Turner, R R Holman.   

Abstract

OBJECTIVE: To determine the relation between systolic blood pressure over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes.
DESIGN: Prospective observational study.
SETTING: 23 hospital based clinics in England, Scotland, and Northern Ireland. PARTICIPANTS: 4801 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of relative risk. OUTCOME MEASURES: Primary predefined aggregate clinical outcomes: any complications or deaths related to diabetes and all cause mortality. Secondary aggregate outcomes: myocardial infarction, stroke, lower extremity amputation (including death from peripheral vascular disease), and microvascular disease (predominantly retinal photocoagulation). Single end points: non-fatal heart failure and cataract extraction. Risk reduction associated with a 10 mm Hg decrease in updated mean systolic blood pressure adjusted for specific confounders.
RESULTS: The incidence of clinical complications was significantly associated with systolic blood pressure, except for cataract extraction. Each 10 mm Hg decrease in updated mean systolic blood pressure was associated with reductions in risk of 12% for any complication related to diabetes (95% confidence interval 10% to 14%, P<0.0001), 15% for deaths related to diabetes (12% to 18%, P<0.0001), 11% for myocardial infarction (7% to 14%, P<0.0001), and 13% for microvascular complications (10% to 16%, P<0.0001). No threshold of risk was observed for any end point.
CONCLUSIONS: In patients with type 2 diabetes the risk of diabetic complications was strongly associated with raised blood pressure. Any reduction in blood pressure is likely to reduce the risk of complications, with the lowest risk being in those with systolic blood pressure less than 120 mm Hg.

Entities:  

Mesh:

Year:  2000        PMID: 10938049      PMCID: PMC27455          DOI: 10.1136/bmj.321.7258.412

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  53 in total

1.  Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus.

Authors:  G Bruno; F Merletti; P Boffetta; P Cavallo-Perin; G Bargero; G Gallone; G Pagano
Journal:  Diabetologia       Date:  1999-03       Impact factor: 10.122

2.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J Tuomilehto; D Rastenyte; W H Birkenhäger; L Thijs; R Antikainen; C J Bulpitt; A E Fletcher; F Forette; A Goldhaber; P Palatini; C Sarti; R Fagard
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

3.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

4.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

Review 5.  Evidence-based medicine and ACE inhibition.

Authors:  C Borghi; E Ambrosioni
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

6.  Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial.

Authors:  L P Svetkey; D Simons-Morton; W M Vollmer; L J Appel; P R Conlin; D H Ryan; J Ard; B M Kennedy
Journal:  Arch Intern Med       Date:  1999-02-08

Review 7.  Effect of ACE inhibition on myocardial ischaemia.

Authors:  R Ferrari
Journal:  Eur Heart J       Date:  1998-09       Impact factor: 29.983

Review 8.  1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association.

Authors:  S Meltzer; L Leiter; D Daneman; H C Gerstein; D Lau; S Ludwig; J F Yale; B Zinman; D Lillie
Journal:  CMAJ       Date:  1998       Impact factor: 8.262

9.  Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study.

Authors:  M Wei; S P Gaskill; S M Haffner; M P Stern
Journal:  Diabetes Care       Date:  1998-07       Impact factor: 19.112

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  445 in total

1.  Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed.

Authors:  R Holman
Journal:  BMJ       Date:  2000-10-28

2.  Controlling glucose and blood pressure in type 2 diabetes.

Authors:  J Tuomilehto
Journal:  BMJ       Date:  2000-08-12

3.  The management of diabetes.

Authors:  S J Griffin
Journal:  BMJ       Date:  2001-10-27

4.  Blood pressure control and diabetic retinopathy.

Authors:  R Klein; B E K Klein
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

Review 5.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

6.  Glycaemia and vascular effects of type 2 diabetes. Lowering glucose concentrations may not be of any value in itself.

Authors:  B Budenholzer
Journal:  BMJ       Date:  2001-05-19

7.  Dual blockade of renin-angiotensin system. Data do not support claimed benefit of combination over single treatment.

Authors:  J McCormack; M Levine
Journal:  BMJ       Date:  2001-05-12

8.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

Review 9.  Antihypertensive drugs and the kidney.

Authors:  Mitra K Nadim; Renee Dua; Vito M Campese
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 10.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.